Implicit|||||||||||Expansion|||||||||||0..463|0|Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region Abstract Although the bcr-abl translocation has been shown to be the causative genetic aberration in chronic myeloid leukemia ( CML ) , there is mounting evidence that the deregulation of other genes , such as the transcription factor interferon regulatory factor 4 ( IRF-4 ) , is also implicated in the pathogenesis of CML .||||||||465..632|1|Promoter methylation of CpG target sites or direct deletions/insertions of genes are mechanisms of a reversible or permanent silencing of gene expression , respectively .|||||||||||||
Implicit|||||||||||Expansion|||||||||||634..779|2|Therefore , we investigated whether IRF-4 promoter methylation or mutation may be involved in the regulation of IRF-4 expression in leukemia cells .||||||||781..1012|3|Whereas promoter mutations or structural rearrangements could be excluded as a cause of altered IRF-4 expression in hematopoietic cells , the IRF-4 promoter methylation status was found to significantly influence IRF-4 transcription .|||||||||||||
Implicit|||||||||||Expansion|||||||||||781..1012|3|Whereas promoter mutations or structural rearrangements could be excluded as a cause of altered IRF-4 expression in hematopoietic cells , the IRF-4 promoter methylation status was found to significantly influence IRF-4 transcription .||||||||1014..1234|4|First , treatment of IRF-4-negative lymphoid , myeloid and monocytic cell lines with the methylation-inhibitor 5-aza-2-deoxycytidine resulted in a time - and concentration-dependent increase of IRF-4 mRNA and protein levels .|||||||||||||
Implicit|||||||||||Expansion|||||||||||1014..1234|4|First , treatment of IRF-4-negative lymphoid , myeloid and monocytic cell lines with the methylation-inhibitor 5-aza-2-deoxycytidine resulted in a time - and concentration-dependent increase of IRF-4 mRNA and protein levels .||||||||1236..1396|5|Second , using a restriction-PCR-assay and bisulfite-sequencing we identified specifically methylated CpG sites in IRF-4-negative but not in IRF-4-positive cells .|||||||||||||
Implicit|||||||||||Expansion|||||||||||1236..1396|5|Second , using a restriction-PCR-assay and bisulfite-sequencing we identified specifically methylated CpG sites in IRF-4-negative but not in IRF-4-positive cells .||||||||1398..1649|6|Third , we clearly determined promoter methylation as a mechanism for IRF-4 down-regulation via reporter gene assays , but did not detect an association of methylational status and mRNA expression of DNA methyltransferases or methyl-CpG-binding proteins .|||||||||||||
EntRel||||||||||||||||||||||1798..2082|8|INTRODUCTION Chronic myeloid leukemia ( CML ) is a clonal myeloproliferative disorder with a typical three phased course ( chronic , accelerated and blastic phase ) reflecting the loss of differentiation and malignant progress which inevitably leads to death after the blastic phase ( 1,2 ) .||||||||2084..2262|9|The hallmark genetic aberration of CML is a reciprocal chromosomal translocation t ( 9 ; 22 ) leading to expression of a bcr-abl fusion gene , an aberrant activated tyrosine kinase ( 2 ) .|||||||||||||
EntRel||||||||||||||||||||||2084..2262|9|The hallmark genetic aberration of CML is a reciprocal chromosomal translocation t ( 9 ; 22 ) leading to expression of a bcr-abl fusion gene , an aberrant activated tyrosine kinase ( 2 ) .||||||||2264..2419|10|Treatment with interferon α ( IFN-α ) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5 – 33 % of CML patients ( 1,2 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||2264..2419|10|Treatment with interferon α ( IFN-α ) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5 – 33 % of CML patients ( 1,2 ) .||||||||2421..2574|11|Recently , we described an impaired expression of the interferon regulatory factor 4 ( IRF-4 ) in CML , correlating with poor response to IFN-α treatment ( 3 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||2576..2634|12|The cause of the silencing of IRF-4 level remained unclear .||||||||2638..2782|13|Interferon regulatory factors ( IRFs ) are a family of transcriptional regulators defined by a characteristic homology in their DNA-binding domain .|||||||||||||
Implicit|||||||||||Expansion|||||||||||2638..2782|13|Interferon regulatory factors ( IRFs ) are a family of transcriptional regulators defined by a characteristic homology in their DNA-binding domain .||||||||2784..2939|14|They play an important role in the regulation of various genes ( such as IFNs , interleukins , MHC class I/II ) , apoptosis and differentiation/maturation ( 4 – 6 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||2784..2939|14|They play an important role in the regulation of various genes ( such as IFNs , interleukins , MHC class I/II ) , apoptosis and differentiation/maturation ( 4 – 6 ) .||||||||2941..3095|15|IRF-4 ( ICSAT/Pip/MUM1 / LSIRF ) is one member with very restricted expression pattern : Predominately B - and activated T-lymphocytes are IRF-4 positive ( 7 – 11 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||2941..3095|15|IRF-4 ( ICSAT/Pip/MUM1 / LSIRF ) is one member with very restricted expression pattern : Predominately B - and activated T-lymphocytes are IRF-4 positive ( 7 – 11 ) .||||||||3097..3274|16|In contrast to other IRFs , expression of IRF-4 can not be induced by IFNs , but by antigen stimulation , crosslinking of T - or B-cell receptors or phorbol-myristate-acetate ( 10,11 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||3097..3274|16|In contrast to other IRFs , expression of IRF-4 can not be induced by IFNs , but by antigen stimulation , crosslinking of T - or B-cell receptors or phorbol-myristate-acetate ( 10,11 ) .||||||||3276..3534|17|Consistent with the restriction of expression to immunocompetent cells , mice with deletion of IRF-4 failed to develop mature and functionally active B - and T-lymphocytes ( 12 ) , and the impaired expression of IRF-4 in CML was predominately found in T-cells ( 3 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||3536..3611|18|These data suggest a crucial role for IRF-4 in the function of immune cells .||||||||3615..3850|19|Methylation of dinucleotide cytosine-guanosine motifs ( CpG ) , especially in CpG islands located in promoter regions , is one of the mechanisms of gene regulation in mammals and a common event of gene silencing in human neoplasias ( 13,14 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||3615..3850|19|Methylation of dinucleotide cytosine-guanosine motifs ( CpG ) , especially in CpG islands located in promoter regions , is one of the mechanisms of gene regulation in mammals and a common event of gene silencing in human neoplasias ( 13,14 ) .||||||||3852..3968|20|As opposed to normal cells , hypermethylation of CpG islands is a frequently observed phenomenon in every cancer type .|||||||||||||
EntRel||||||||||||||||||||||3970..4132|21|De novo DNA methylation of genes such as cell cycle , DNA repair , apoptosis and tumor suppressor genes is therefore thought to be involved in tumorigenesis ( 15 – 17 ) .||||||||4134..4243|22|Examples for such aberrated genes are MGMT , DAPK , p14ARF , p15INK4b , p16INK4a , BRCA1 , CDH13 and APAF-1 ( 17 – 19 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||4134..4243|22|Examples for such aberrated genes are MGMT , DAPK , p14ARF , p15INK4b , p16INK4a , BRCA1 , CDH13 and APAF-1 ( 17 – 19 ) .||||||||4245..4454|23|In CML , methylation is known to regulate expression of the c-abl , the bcr gene and others ( 20 – 23 ) , and the extent of methylation in the c-abl promoter has been shown to be associated with advanced disease ( 24 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||4245..4454|23|In CML , methylation is known to regulate expression of the c-abl , the bcr gene and others ( 20 – 23 ) , and the extent of methylation in the c-abl promoter has been shown to be associated with advanced disease ( 24 ) .||||||||4456..4602|24|Hypermethylation due to overexpression of DNA methyltransferases ( DNMTs ) remains one possible explanation for de novo methylation in tumorigenesis .|||||||||||||
Implicit|||||||||||Expansion|||||||||||4456..4602|24|Hypermethylation due to overexpression of DNA methyltransferases ( DNMTs ) remains one possible explanation for de novo methylation in tumorigenesis .||||||||4604..4689|25|Recently , DNMTs have been shown to be up-regulated in hematopoietic malignancies ( 25 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||4691..4901|26|Methyl-CpG-binding proteins ( MBPs ) are thought to inhibit the binding of transcriptional factors to the promoter and are therefore discussed as one mechanism of transcription inhibition by hypermethylation ( 26 ) .||||||||4905..4993|27|In this work , we studied mechanisms of IRF-4 gene expression silencing in leukemic cells .|||||||||||||
Implicit|||||||||||Expansion|||||||||||5417..5487|30|All cell lines , except BV-173 , SD-1 and RPMI-8226 , were IRF-4-negative .||||||||5491..5708|31|All cell lines were maintained at 5 % CO2 in RPMI 1640 medium with 1 % glutamine ( Gibco/BRL Eggenstein , Germany ) supplemented with 10 % fetal calf serum ( Gibco/BRL ) , 1 % penicillin/streptomycin ( Biochrom , Berlin , Germany ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||5491..5708|31|All cell lines were maintained at 5 % CO2 in RPMI 1640 medium with 1 % glutamine ( Gibco/BRL Eggenstein , Germany ) supplemented with 10 % fetal calf serum ( Gibco/BRL ) , 1 % penicillin/streptomycin ( Biochrom , Berlin , Germany ) .||||||||5710..5860|32|When indicated , cells were treated with 5-aza-2-deoxycytidine ( AzadC ) or 5-azacytidine ( AzaC ) ( Sigma , Taufkirchen , Germany ) for different time periods .|||||||||||||
EntRel||||||||||||||||||||||5862..6208|33|Owing to their chemical instability fresh substances were re-added every 24 h. For analysis of the IRF-4 promoter region for permanent aberrations such as insertions/deletions or mutation , we PCR-amplified two fragments from genomic DNA , which was extracted from depicted cell lines with a commercial kit ( Qiagen , Hilde , Germany ) as recommended .||||||||6210..6391|34|The primers were 1-forward : 5 ′ - TTGAGATGGAGTCTTGCTCTGT-3 ′ , 1-reverse : 5 ′ - CCAGGACCTCAGGAGGCCAGTCA-3 ′ ; 2-forward : 5 ′ - AGCGGTGAAACTGAGAGTGCGAGGT-3 ′ , 2-reverse : 5 ′ - GCCACATCGCTGCAGTTTAG-3 ′ .|||||||||||||
EntRel||||||||||||||||||||||6210..6391|34|The primers were 1-forward : 5 ′ - TTGAGATGGAGTCTTGCTCTGT-3 ′ , 1-reverse : 5 ′ - CCAGGACCTCAGGAGGCCAGTCA-3 ′ ; 2-forward : 5 ′ - AGCGGTGAAACTGAGAGTGCGAGGT-3 ′ , 2-reverse : 5 ′ - GCCACATCGCTGCAGTTTAG-3 ′ .||||||||6393..6489|35|The products were cloned with the ' TOPO TA cloning kit ' ( Invitrogen , Groningen , The Netherlands ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||6491..6744|36|After bacterial amplification of the cloned PCR fragments by standard procedures , at least three clones from each sample were sequenced with an automated sequencer ( ABI Prism 377 , Applied Bio-systems , Foster City , USA ) as recommended by the manufacturer .||||||||6748..6881|37|To analyze the IRF-4 transcriptional level , RNA was extracted from cells using the commercial RNAzol-kit ( Paesel , Frankfurt , Germany ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||6748..6881|37|To analyze the IRF-4 transcriptional level , RNA was extracted from cells using the commercial RNAzol-kit ( Paesel , Frankfurt , Germany ) .||||||||6883..6968|38|An aliquot of 1 μg total RNA was used for cDNA synthesis as described previously ( 27 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||6883..6968|38|An aliquot of 1 μg total RNA was used for cDNA synthesis as described previously ( 27 ) .||||||||6970..7106|39|RNA expression analysis for IRF-4 and the reference gene β-actin was carried out by semi-quantitative PCR as described previously ( 3,27 ) .|||||||||||||
EntRel||||||||||||||||||||||6970..7106|39|RNA expression analysis for IRF-4 and the reference gene β-actin was carried out by semi-quantitative PCR as described previously ( 3,27 ) .||||||||7108..7158|40|PCR products were verified by automated sequencing .|||||||||||||
Implicit|||||||||||Expansion|||||||||||7160..7305|41|PCR primers and conditions for expression analysis of DNMT or MBP ( DNMT1 DNMT3A , DNMT3B , MeCP , MBD1 , MBD2 and MBD4 ) were published elsewhere ( 28 ) .||||||||7309..7425|42|For analysis of IRF-4 protein expression , a standard immunoblotting assay was performed as described previously ( 29 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||7309..7425|42|For analysis of IRF-4 protein expression , a standard immunoblotting assay was performed as described previously ( 29 ) .||||||||7427..7716|43|Briefly , protein lysates were generated by incubating 1 × 106 cells in 100 µl RIPA buffer ( 1 % NP-40 , 0.5 % sodiumdesoxycholate , 0.1 % SDS , 100 µg / ml phenylmethylsulfonyl fluoride , 10 µl / ml protease-inhibitory-mix , 1 µmol / ml sodiumorthovanadate in phosphate-buffered saline ) for 30 min on ice .|||||||||||||
Implicit|||||||||||Expansion|||||||||||7427..7716|43|Briefly , protein lysates were generated by incubating 1 × 106 cells in 100 µl RIPA buffer ( 1 % NP-40 , 0.5 % sodiumdesoxycholate , 0.1 % SDS , 100 µg / ml phenylmethylsulfonyl fluoride , 10 µl / ml protease-inhibitory-mix , 1 µmol / ml sodiumorthovanadate in phosphate-buffered saline ) for 30 min on ice .||||||||7718..7847|44|After centrifugation , protein concentration of the supernatant was determined by BCA-method ( Pierce , Rockford , IL ) as recommended .|||||||||||||
Implicit|||||||||||Expansion|||||||||||7718..7847|44|After centrifugation , protein concentration of the supernatant was determined by BCA-method ( Pierce , Rockford , IL ) as recommended .||||||||7849..8008|45|Protein lysates ( 70 – 100 µg ) were electrophoresed on polyacrylamide gels and transferred to a PVDF-membrane ( Immobilon P , 0.45 µm ; Millipore , Eschborn , Germany ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||7849..8008|45|Protein lysates ( 70 – 100 µg ) were electrophoresed on polyacrylamide gels and transferred to a PVDF-membrane ( Immobilon P , 0.45 µm ; Millipore , Eschborn , Germany ) .||||||||8010..8386|46|Membranes were blocked with 2.5 % blocking reagent ( Boehringer Mannheim , Germany ) in TBST buffer ( 4.44 g/l Tris – HCL , 2.65 g/l TrisOH , 8.07 g/l NaCl , 0.2 g/l KCl and 500 µl / l Tween-20 in H2O ) and subsequently incubated with primary antibody as indicated and horseradish peroxidase-conjugated secondary antibody , anti-mouse or anti-goat IgG ( DAKO , Hamburg , Germany ) , respectively .|||||||||||||
EntRel||||||||||||||||||||||8497..8635|48|The primary antibodies were goat anti-IRF-4 / ICSAT ( M-17 ) ( Santa Cruz Biotechnology , Santa Cruz , CA ) and mouse anti-β-actin ( AC-74 ) ( Sigma ) .||||||||8639..8702|49|DNA was extracted with a commercial kit ( Qiagen ) as recommended .|||||||||||||
Implicit|||||||||||Expansion|||||||||||8639..8702|49|DNA was extracted with a commercial kit ( Qiagen ) as recommended .||||||||8704..8946|50|Since the restriction ability of several endonucleases is inhibited by methylation of their target sequence , we used methylation-sensitive enzymes HpaII and HaeII-isochizomer Bsp143II and Bsh1236I ( MBI Fermentas , St Leon-Rot , Germany ) ( 20,24 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||8704..8946|50|Since the restriction ability of several endonucleases is inhibited by methylation of their target sequence , we used methylation-sensitive enzymes HpaII and HaeII-isochizomer Bsp143II and Bsh1236I ( MBI Fermentas , St Leon-Rot , Germany ) ( 20,24 ) .||||||||8948..9076|51|As control the methylation-resistant enzyme MspI and an enzyme with no recognition site in the target promoter , EcoRI , were used .|||||||||||||
Implicit|||||||||||Expansion|||||||||||9078..9369|52|DNA ( 0.8 µg ) was digested by 40 U the respective enzyme for 6 h and , to ensure complete cleavage , additional 20 U for 16 h. Thereafter 100 ng of digested DNA was used to a PCR amplification of two fragments ( F1 and F2 ) spanning part of the IRF-4 promoter ( 30 ) ( GenBank U52683 ; see Figure 3A ) .||||||||9371..9593|53|The sequences of the primers were F1-forward : 5 ′ - TTGAGATGGAGTCTTGCTCTGT-3 ′ , F1-reverse : ATCACTTCCAGACTTCAGTTCACCT-3 ′ ( 341 bp ) ; F2-forward : 5 ′ - AAGGTGAACTGAAGTCTGGAAGTGA-3 ′ , F2-reverse : 5 ′ - CCAGGACCTCAGGAGGCCAGTCA-3 ′ ( 474 bp ) .|||||||||||||
EntRel||||||||||||||||||||||9371..9593|53|The sequences of the primers were F1-forward : 5 ′ - TTGAGATGGAGTCTTGCTCTGT-3 ′ , F1-reverse : ATCACTTCCAGACTTCAGTTCACCT-3 ′ ( 341 bp ) ; F2-forward : 5 ′ - AAGGTGAACTGAAGTCTGGAAGTGA-3 ′ , F2-reverse : 5 ′ - CCAGGACCTCAGGAGGCCAGTCA-3 ′ ( 474 bp ) .||||||||9595..9642|54|The PCR conditions were described elsewhere ( 3 ) .|||||||||||||
EntRel||||||||||||||||||||||9595..9642|54|The PCR conditions were described elsewhere ( 3 ) .||||||||9644..9713|55|PCR was performed with an annealing temperature of 62 ° C and 35 cycles .|||||||||||||
Implicit|||||||||||Expansion|||||||||||9644..9713|55|PCR was performed with an annealing temperature of 62 ° C and 35 cycles .||||||||9715..9914|56|When DNA was methylated at specific sites , the sensitive enzymes were not able to digest the DNA and amplification took place ; in case of no methylation , DNA was digested and no product was generated .|||||||||||||
Implicit|||||||||||Expansion|||||||||||9715..9914|56|When DNA was methylated at specific sites , the sensitive enzymes were not able to digest the DNA and amplification took place ; in case of no methylation , DNA was digested and no product was generated .||||||||9916..10026|57|The PCR products were electrophoresed on a 3 % agarose gel , were stained with ethidium bromide and photographed .|||||||||||||
Implicit|||||||||||Expansion|||||||||||7108..7158|58|PCR products were verified by automated sequencing .||||||||10082..10118|59|DNA was extracted as described above .|||||||||||||
Implicit|||||||||||Expansion|||||||||||10082..10118|59|DNA was extracted as described above .||||||||10120..10298|60|Bisulfite treatment of DNA , leading to conversion of unmethylated cytosine to uracil residues and no change of methylated cytosine residues , was performed as described as follows .|||||||||||||
Implicit|||||||||||Expansion|||||||||||10120..10298|60|Bisulfite treatment of DNA , leading to conversion of unmethylated cytosine to uracil residues and no change of methylated cytosine residues , was performed as described as follows .||||||||10300..10467|61|Briefly , 1 µg of DNA and 2 µg of poly ( dA – dT ) ( poly ( dA – dT ) copolymers ( Amersham Pharmacia Biotech ) were denaturated for 20 min at 42 ° C in 0.3 M NaOH in a volume of 50 µl .|||||||||||||
Implicit|||||||||||Expansion|||||||||||10300..10467|61|Briefly , 1 µg of DNA and 2 µg of poly ( dA – dT ) ( poly ( dA – dT ) copolymers ( Amersham Pharmacia Biotech ) were denaturated for 20 min at 42 ° C in 0.3 M NaOH in a volume of 50 µl .||||||||10469..10689|62|Fresh solutions of 30 µl of 10 mM hydrochinon ( Sigma ) and 530 µl of 3 M sodium bisulfite ( pH 5.0 ; Sigma ) were added , the solution was gently mixed , overlayed with mineral oil and incubated in the dark for 12 – 13 h at 50 ° C .|||||||||||||
EntRel||||||||||||||||||||||10469..10689|62|Fresh solutions of 30 µl of 10 mM hydrochinon ( Sigma ) and 530 µl of 3 M sodium bisulfite ( pH 5.0 ; Sigma ) were added , the solution was gently mixed , overlayed with mineral oil and incubated in the dark for 12 – 13 h at 50 ° C .||||||||10691..10790|63|The aqueous phase was recovered using the ' Wizard DNA clean-up system ' ( Promega , Mannheim , Germany ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||10691..10790|63|The aqueous phase was recovered using the ' Wizard DNA clean-up system ' ( Promega , Mannheim , Germany ) .||||||||10792..10947|64|The purified DNA was subsequently mixed with 1 M NaOH to a final concentration of 0.3 M and incubated for 20 min at 37 ° C to ensure complete desulfonisation .|||||||||||||
Implicit|||||||||||Expansion|||||||||||10792..10947|64|The purified DNA was subsequently mixed with 1 M NaOH to a final concentration of 0.3 M and incubated for 20 min at 37 ° C to ensure complete desulfonisation .||||||||10949..11081|65|DNA was ethanol precipitated in the presence of 1/10 vol of 3 M sodium acetate , washed with 70 % ethanol and resuspended in 50 µl H2O .|||||||||||||
Implicit|||||||||||Expansion|||||||||||10949..11081|65|DNA was ethanol precipitated in the presence of 1/10 vol of 3 M sodium acetate , washed with 70 % ethanol and resuspended in 50 µl H2O .||||||||11083..11297|66|Subsequent PCR amplification of 4 µl bisulfite-treated DNA was used for cloning of two fragments of the IRF-4 promoter ( BS-I and BS-II ) into pCR2 .1 vector with the ' TOPO TA cloning kit ' ( Invitrogen ) ( see Figure 3A ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||11083..11297|66|Subsequent PCR amplification of 4 µl bisulfite-treated DNA was used for cloning of two fragments of the IRF-4 promoter ( BS-I and BS-II ) into pCR2 .1 vector with the ' TOPO TA cloning kit ' ( Invitrogen ) ( see Figure 3A ) .||||||||11299..11721|67|The primers used for PCR amplification of the BS-I and BS-II fragments contain the putative altered sequence of the sense strand due to bisulfite treatment ( converted cytosine residues are written in bold letters ) : BS-I-forward 5 ′ - TATTTGGATTTTTAGGGAGTTTTTTTT-3 ′ , BS-I-reverse 5 ′ - ACCCAACTCCCTTAAACTATTAAACT-3 ′ ( 187 bp ) ; BS-II-forward 5 ′ - AGTTTAATAGTTTAAGGGAGTTGGGT-3 ′ , BS-II-reverse 5 ′ - CTCACCCTAAACTCAAAACTAAAAAC-3 ′ ( 674 bp ) .|||||||||||||
EntRel||||||||||||||||||||||6491..6683|68|After bacterial amplification of the cloned PCR fragments by standard procedures , eight clones from each sample were sequenced with an automated sequencer ( ABI Prism 377 , Applied Biosystems ) .||||||||11917..12002|69|The IRF-4 promoter-reporter gene construct was generously provided by J. Hiscott ( 31 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||11917..12002|69|The IRF-4 promoter-reporter gene construct was generously provided by J. Hiscott ( 31 ) .||||||||12004..12190|70|Constructs were methylated in vitro with CpG Methylase ( M.Sss I ) as recommended by the manufacturer ( NE Biolabs ) and complete methylation was checked via restriction analysis ( Figure 5A ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||12004..12190|70|Constructs were methylated in vitro with CpG Methylase ( M.Sss I ) as recommended by the manufacturer ( NE Biolabs ) and complete methylation was checked via restriction analysis ( Figure 5A ) .||||||||12192..12302|71|Reporter gene assays using the dual luciferase assay ( Promega ) were performed similar to previous reports ( 29 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||12192..12302|71|Reporter gene assays using the dual luciferase assay ( Promega ) were performed similar to previous reports ( 29 ) .||||||||12304..12470|72|Briefly , 5 nM of the reporter construct and the transfection control construct expressing the renilla luciferase gene were transientlyco-expressed via electroporation .|||||||||||||
Implicit|||||||||||Expansion|||||||||||12304..12470|72|Briefly , 5 nM of the reporter construct and the transfection control construct expressing the renilla luciferase gene were transientlyco-expressed via electroporation .||||||||12472..12553|73|The control construct served as an internal reference for transfection efficiency .|||||||||||||
Implicit|||||||||||Expansion|||||||||||12472..12553|73|The control construct served as an internal reference for transfection efficiency .||||||||12555..12689|74|Forty-eight hours after transfection , luciferase activity was measured with a LB 96 P microlumat ( EG&G Berthold , Bad Wildbad , Germany ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||12555..12689|74|Forty-eight hours after transfection , luciferase activity was measured with a LB 96 P microlumat ( EG&G Berthold , Bad Wildbad , Germany ) .||||||||12691..12806|75|IRF-4 promoter activation was quantified as a ratio of measured firefly light units ( flu ) relative to renilla ( rlu ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||12864..12988|77|RESULTS We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells ( 3 ) .||||||||12990..13448|78|Here , we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines , such as Jurkat , a T-cell leukemia , CML-T1 , a bcr-abl-positive T-cell line , K-562 , a bcr-abl-positve erythroleukemia , U-937 , a monocytic leukemia , EM-2 and LAMA-84 , bcr-abl-positve myeloid leukemia , but not in SD-1 , a bcr-abl-positive acute lymphoblastic leukemia ( pre B-ALL ) , RPMI-8226 , a multiple myeloma and BV-173 , a bcr-abl-positive B-cell line ( Figures 1A and 5D ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||12990..13448|78|Here , we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines , such as Jurkat , a T-cell leukemia , CML-T1 , a bcr-abl-positive T-cell line , K-562 , a bcr-abl-positve erythroleukemia , U-937 , a monocytic leukemia , EM-2 and LAMA-84 , bcr-abl-positve myeloid leukemia , but not in SD-1 , a bcr-abl-positive acute lymphoblastic leukemia ( pre B-ALL ) , RPMI-8226 , a multiple myeloma and BV-173 , a bcr-abl-positive B-cell line ( Figures 1A and 5D ) .||||||||13450..13605|79|After sequencing of the IRF-4 promoter , it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations .|||||||||||||
Implicit|||||||||||Expansion|||||||||||13607..13778|80|However , 2 bp changes ( nucleotide − 1081 , T → C and − 1068 , A → C ) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84 , EM-2 and K-562 ( Figure 1B ) .||||||||13780..13984|81|At position − 116 an A → C substitution was found in EM-2 , K-562 and CML-T1 , whereas Jurkat , BV-173 and SD-1 exhibited a mixed A/C sequence and U-937 , LAMA-84 and RPMI-8226 no substitution at all ( Figure 1B ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||14061..14167|83|We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression .||||||||14169..14274|84|A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences ( Figure 3A ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||14169..14274|84|A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences ( Figure 3A ) .||||||||14276..14471|85|Several chemical substances such as 5-aza-2-deoxycytidine ( AzadC ) or 5-azacytidine ( AzaC ) inhibit de novo and maintenance methylation , and thus can be used to discern promoter methylation ( 32,33 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||14276..14471|85|Several chemical substances such as 5-aza-2-deoxycytidine ( AzadC ) or 5-azacytidine ( AzaC ) inhibit de novo and maintenance methylation , and thus can be used to discern promoter methylation ( 32,33 ) .||||||||14473..14515|86|We used AzadC to generate unmethylated DNA .|||||||||||||
Implicit|||||||||||Expansion|||||||||||14473..14515|86|We used AzadC to generate unmethylated DNA .||||||||14517..14699|87|A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937 , K-562 and EM-2 cell lines ( Figure 2A ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||14517..14699|87|A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937 , K-562 and EM-2 cell lines ( Figure 2A ) .||||||||14701..14867|88|IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h ( Figure 2B ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||14701..14867|88|IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h ( Figure 2B ) .||||||||14869..15018|89|Time and strength of the appearance of IRF-4 transcripts varied among cell lines , i.e. CML-T1 responded strongest to AzadC-treatment ( data not shown ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||15156..15294|91|Accordingly , treatment of the IRF-4-positive cell line BV-173 , SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression ( Figure 2D ) .||||||||15296..15436|92|There was no difference in the effects of AzaC versus AzadC , as both increased the IRF-4 mRNA level in CML-T1 cells as well ( data not shown ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||15438..15622|93|This implied that promoter methylation may control IRF-4 expression , but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC ( or AzaC ) .||||||||15626..15864|94|To further investigate promoter methylation as a regulatory mechanism of IRF-4 gene expression , restriction-PCR-assays were performed ( 20,24 ) , where only methylated DNA would not be cut enabling subsequent PCR amplification and vice versa .|||||||||||||
Implicit|||||||||||Expansion|||||||||||15626..15864|94|To further investigate promoter methylation as a regulatory mechanism of IRF-4 gene expression , restriction-PCR-assays were performed ( 20,24 ) , where only methylated DNA would not be cut enabling subsequent PCR amplification and vice versa .||||||||15866..16042|95|Genomic DNA from leukemic cells Jurkat , CML-T1 , U-937 , K-562 , EM-2 and BV-173 was digested with the methylation-sensitive enzymes HpaII , Bsh1236I and HaeII-isochizomer Bsp143II .|||||||||||||
EntRel||||||||||||||||||||||15866..16042|95|Genomic DNA from leukemic cells Jurkat , CML-T1 , U-937 , K-562 , EM-2 and BV-173 was digested with the methylation-sensitive enzymes HpaII , Bsh1236I and HaeII-isochizomer Bsp143II .||||||||16044..16168|96|EcoRI , which has no recognition site within the IRF-4 promoter , and the methylation-resistant enzyme MspI served as controls .|||||||||||||
EntRel||||||||||||||||||||||16044..16168|96|EcoRI , which has no recognition site within the IRF-4 promoter , and the methylation-resistant enzyme MspI served as controls .||||||||16170..16270|97|Two separate amplification reactions were performed , generating two fragments , F1 and F2 ( Figure 3A ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||16170..16270|97|Two separate amplification reactions were performed , generating two fragments , F1 and F2 ( Figure 3A ) .||||||||16272..16557|98|After digestion with HpaII and Bsp143II a sufficient PCR amplification of F1 and F2 was detected in DNA from IRF-4-negative Jurkat , CML-T1 , U-937 , K-562 and EM-2 cells , suggesting a promoter methylation ( and restriction protection ) at the respective recognition sites ( Figure 3B and C ) .|||||||||||||
EntRel||||||||||||||||||||||16272..16557|98|After digestion with HpaII and Bsp143II a sufficient PCR amplification of F1 and F2 was detected in DNA from IRF-4-negative Jurkat , CML-T1 , U-937 , K-562 and EM-2 cells , suggesting a promoter methylation ( and restriction protection ) at the respective recognition sites ( Figure 3B and C ) .||||||||16559..16693|99|Notably , in IRF-4-positive SD-1 cells digestion with the methylation-sensitive enzymes completely inhibited amplification of F1 and F2 .|||||||||||||
Implicit|||||||||||Expansion|||||||||||16559..16693|99|Notably , in IRF-4-positive SD-1 cells digestion with the methylation-sensitive enzymes completely inhibited amplification of F1 and F2 .||||||||16695..16890|100|In IRF-4-positive BV-173 cells a HpaII , but not a Bsh1236I digestion , significantly reduced the amplifiable DNA message of F2 ( Figure 3C ) , whereas amplification of F1 was not affected ( Figure 3B ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||16892..17086|101|This implied that IRF-4 transcription in SD-1 and BV-173 cells is associated with less promoter methylation ( in BV-173 especially at HpaII sites ) as compared with the tested IRF-4-negative cells .||||||||17090..17420|102|In order to exactly map the methylation sites within the IRF-4 promoter , we treated DNA of Jurkat , CML-T1 , U-937 , K-562 and EM-2 cells as well as of SD-1 , RPMI-8226 and BV-173 control cells with bisulfite , which chemically converts unmethylated cytosine to uracil , whereas it has no effect on methylated cytosine , i.e. in CpG ( 34 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||17090..17420|102|In order to exactly map the methylation sites within the IRF-4 promoter , we treated DNA of Jurkat , CML-T1 , U-937 , K-562 and EM-2 cells as well as of SD-1 , RPMI-8226 and BV-173 control cells with bisulfite , which chemically converts unmethylated cytosine to uracil , whereas it has no effect on methylated cytosine , i.e. in CpG ( 34 ) .||||||||17422..17503|103|This technique is especially useful for detection of unknown methylation patterns .|||||||||||||
Implicit|||||||||||Expansion|||||||||||17422..17503|103|This technique is especially useful for detection of unknown methylation patterns .||||||||17505..17683|104|PCR amplification , cloning and sequencing of the bisulfite-treated DNA showed a specific methylation pattern of the analyzed 62 CpG sites in all cell lines ( Figure 4 and Table 1 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||17505..17683|104|PCR amplification , cloning and sequencing of the bisulfite-treated DNA showed a specific methylation pattern of the analyzed 62 CpG sites in all cell lines ( Figure 4 and Table 1 ) .||||||||17685..17883|105|In general , the methylational status ranged from one cell line with a nearly non-methylated IRF-4 promoter ( SD-1 , IRF-4-positive ) to a completely methylated IRF-4 promoter in CML-T1 ( IRF-4-negative ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||17685..17883|105|In general , the methylational status ranged from one cell line with a nearly non-methylated IRF-4 promoter ( SD-1 , IRF-4-positive ) to a completely methylated IRF-4 promoter in CML-T1 ( IRF-4-negative ) .||||||||17885..18078|106|Interestingly , the percentage of CpG methylation in the IRF-4 promoter from IRF-4-positive cells was very low ( mean 24 % ) as compared with IRF-4-negative cells ( mean 94 % ) ( Figure 4A and Table 1 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||18080..18445|107|A 5 ′ - region ( R1 ) with 13 hypermethylated CpG sites ( mean number of methylated clones 5.5 of 8 with 77 % methylated CpGs ) was found in most cells ( except SD-1 and RPMI-8226 ) and a 3 ′ - region ( R3 ) of 6 hypomethylated CpG sites ( mean number of methylated clones 1.7 of 8 with 33 % methylated CpGs ) was found in most cells ( except CML-T1 and U-937 ) ( Figure 4A and Table 1 ) .||||||||18449..18725|108|Intriguingly , a stretch of 13 CpG sites ( # 10 – 22 ; R2 ) was detected in between these regions , which were highly methylated in IRF-4-negative ( mean number of methylated clones 7.1 of 8 with 89 % methylated CpGs ) but totally non-methylated in IRF-4-positive cells ( Figure 4A and B ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||19115..19228|111|These results indicate the involvement of CpG methylation in the regulation of IRF-4 expression in leukemic cells .||||||||19232..19431|112|To provide evidence for a direct effect of methylational status on IRF-4 promoter activity we performed reporter gene assays with IRF-4 promoter constructs before and after their in vitro methylation .|||||||||||||
Implicit|||||||||||Expansion|||||||||||19232..19431|112|To provide evidence for a direct effect of methylational status on IRF-4 promoter activity we performed reporter gene assays with IRF-4 promoter constructs before and after their in vitro methylation .||||||||19433..19563|113|A complete methylation of these constructs was checked via restriction assays with methylation-sensitive endonucleases ( Figure 5A ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||19433..19563|113|A complete methylation of these constructs was checked via restriction assays with methylation-sensitive endonucleases ( Figure 5A ) .||||||||19565..19704|114|Intriguingly , methylation of the IRF-4 promoter significantly decreased promoter activity in IRF-4-positive SD-1 cells by 85.0 % ( Figure 5B ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||19565..19704|114|Intriguingly , methylation of the IRF-4 promoter significantly decreased promoter activity in IRF-4-positive SD-1 cells by 85.0 % ( Figure 5B ) .||||||||19706..19906|115|The silencing effect of CpG methylation was not restricted to IRF-4-positive cells , since in vitro methylation led to a 92.9 % abrogation of promoter activity in IRF-4-negative Jurkat cells ( Figure 5C ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||20082..20175|117|These data proved a direct association between methylation and activity of the IRF-4 promoter .||||||||20179..20404|118|Since abundance of DNMT and MBP contribute to promoter regulation via methylation ( 25,26,28 ) , we studied their mRNA expression to investigate a possible mechanism for the observed methylation differences in the IRF-4 promoter .|||||||||||||
Implicit|||||||||||Expansion|||||||||||20179..20404|118|Since abundance of DNMT and MBP contribute to promoter regulation via methylation ( 25,26,28 ) , we studied their mRNA expression to investigate a possible mechanism for the observed methylation differences in the IRF-4 promoter .||||||||20406..20602|119|To this end , we did not detect a significant difference in DNMT ( DNMT1 , DNMT3A and DNMT3B ) or MBP ( MBD1 , MBD2 , MBD4 and MeCP ) mRNA expression between IRF-4-positive and - negative cells ( Figure 5D ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||20931..21028|122|DISCUSSION Many genetic lesions are known to influence gene expression of tumor suppressor genes .||||||||21030..21211|123|Whereas mutations and deletions or insertions have permanent effects , reversible mechanisms are gene methylation , or expression and activation of transcription factors , respectively .|||||||||||||
Implicit|||||||||||Expansion|||||||||||21030..21211|123|Whereas mutations and deletions or insertions have permanent effects , reversible mechanisms are gene methylation , or expression and activation of transcription factors , respectively .||||||||21213..21343|124|We studied a putative cause for absent IRF-4 expression in leukemia cells and first focused on genetic aberrations of the promoter .|||||||||||||
Implicit|||||||||||Expansion|||||||||||21213..21343|124|We studied a putative cause for absent IRF-4 expression in leukemia cells and first focused on genetic aberrations of the promoter .||||||||21345..21865|125|We observed no genetic alterations in the IRF-4 promoter , which can account for the lack of IRF-4 expression : The detected base pair changes at position − 1081 ( T → C substitution ) , at position − 1068 ( A → C substitution ) and at position − 116 ( A → C substitution ) are unlikely responsible for absent IRF-4-expression since the first two mutations were found both in IRF-4-positive and - negative cells whereas the latter change was not detected consistently in all IRF-4-negative or - positive cells and may thus be a polymorphism .|||||||||||||
Implicit|||||||||||Expansion|||||||||||21345..21865|125|We observed no genetic alterations in the IRF-4 promoter , which can account for the lack of IRF-4 expression : The detected base pair changes at position − 1081 ( T → C substitution ) , at position − 1068 ( A → C substitution ) and at position − 116 ( A → C substitution ) are unlikely responsible for absent IRF-4-expression since the first two mutations were found both in IRF-4-positive and - negative cells whereas the latter change was not detected consistently in all IRF-4-negative or - positive cells and may thus be a polymorphism .||||||||21867..22055|126|All three substitutions did not change any known putative transcription factor binding sites ( 30,31 ) and also do not affect any restriction sites or primer binding sites of the used assays .|||||||||||||
Implicit|||||||||||Expansion|||||||||||22411..22729|129|We then investigated whether the previously described down-regulation of IRF-4 expression in human myeloid leukemias was due to a differential hypermethylation of the promoter , since the presented re-expression due to AzadC-treatment might also be a result of activation of positive transcriptional regulators of IRF-4 .||||||||22731..22911|130|Methylation of CpG sites is a common mechanism of silencing genes in leukemia and has also been shown for another IRF , IRF-7 ( 35 ) and for PU .1 ( 36 ) , an interacting partner of IRF-4 .|||||||||||||
EntRel||||||||||||||||||||||22731..22911|130|Methylation of CpG sites is a common mechanism of silencing genes in leukemia and has also been shown for another IRF , IRF-7 ( 35 ) and for PU .1 ( 36 ) , an interacting partner of IRF-4 .||||||||22913..23114|131|To elucidate the relevance of this mechanism for the regulation of IRF-4 expression , various leukemic cells were treated with demethylating agents and promoters were sequenced after bisulfite treatment .|||||||||||||
Implicit|||||||||||Expansion|||||||||||22913..23114|131|To elucidate the relevance of this mechanism for the regulation of IRF-4 expression , various leukemic cells were treated with demethylating agents and promoters were sequenced after bisulfite treatment .||||||||23116..23243|132|We found that IRF-4 expression could indeed be connected to the methylation status of distinct CpG motifs in the IRF-4 promoter .|||||||||||||
Implicit|||||||||||Expansion|||||||||||23116..23243|132|We found that IRF-4 expression could indeed be connected to the methylation status of distinct CpG motifs in the IRF-4 promoter .||||||||23245..23394|133|In Figure 4A , those CpG sites are shown ( bottom line ) , whose hypermethylation may account for the absence of IRF-4 expression in the respective cells .|||||||||||||
Implicit|||||||||||Expansion|||||||||||23245..23394|133|In Figure 4A , those CpG sites are shown ( bottom line ) , whose hypermethylation may account for the absence of IRF-4 expression in the respective cells .||||||||23396..23521|134|One of them ( # 54 ) is adjacent to an identified regulatory element ( NFκB-site ) , indicating a possible involvement of this site .|||||||||||||
Implicit|||||||||||Expansion|||||||||||23396..23521|134|One of them ( # 54 ) is adjacent to an identified regulatory element ( NFκB-site ) , indicating a possible involvement of this site .||||||||23523..23642|135|At two further CpG sites ( # 48 , 45 ) the methylation status in IRF-4-positive was lower than that of IRF-4-negative cells .|||||||||||||
Implicit|||||||||||Expansion|||||||||||23644..23770|136|These CpG sites are located in an NFκB and an SP1 element ( 31 ) and thus may also play a role in regulation of IRF-4 expression .||||||||23772..23965|137|It has been shown that NFκB elements play an important role in IRF-4 induction as IRF-4 expression depends on binding of the transactivator c-Rel to these elements in the IRF-4 promoter ( 31,37 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||23967..24188|138|Furthermore , methylation of the central CpG in the NFκB element inhibits binding of the NFκB protein complexes ( 38 ) , promoting the significance of the observed methylation differences in IRF-4-positive and - negative cells .||||||||24192..24389|139|Via in vitro methylation and reporter gene assays we could clearly appoint the silencing of the IRF-4 promoter to a methylation effect , which may thus be the mechanism of IRF-4 deregulation in vivo .|||||||||||||
EntRel||||||||||||||||||||||24192..24389|139|Via in vitro methylation and reporter gene assays we could clearly appoint the silencing of the IRF-4 promoter to a methylation effect , which may thus be the mechanism of IRF-4 deregulation in vivo .||||||||24391..24518|140|One possible cause for the aberrant methylation in tumorigenesis is an increased level of DNMTs during the pathogenetic process .|||||||||||||
Implicit|||||||||||Expansion|||||||||||24391..24518|140|One possible cause for the aberrant methylation in tumorigenesis is an increased level of DNMTs during the pathogenetic process .||||||||24520..24635|141|In colon , lung and hematologic malignancies , overexpression of DNMT1 , a maintenance DNMT , has been detected ( 39 – 41 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||24637..24866|142|Furthermore , it has been shown that CML cells in the acute phase exhibited elevated levels of the three known DNMTs , while CML cells in chronic phase expressed normal levels of DNMTs if compared with normal bone marrow cells ( 25 ) .||||||||24868..25000|143|Interestingly , a positive correlation between DNMT1 expression levels and hypermethylation of p15INK4b has been detected in AML ( 25 ) .|||||||||||||
Implicit|||||||||||Contingency|||||||||||25002..25211|144|In this work , we did not detect significant mRNA expression differences of selected DNMT or MBP , making it an unlikely cause for the observed methylation and thus IRF-4 expression differences in leukemia cells .||||||||25215..25391|145|The finding that IRF-4 expression is silenced by promoter hypermethylation might represent a mechanism that accounts for the previously observed loss of IRF-4 expression in CML .|||||||||||||
Implicit|||||||||||Expansion|||||||||||25393..25584|146|Indeed , several clinical trials with leukemia patients and patients with myelodysplastic syndromes demonstrated the potential clinical benefit of a treatment with demethylating agents ( 42 – 45 ) .||||||||25588..25731|147|The expression of another IRF , IFN consensus sequence binding protein ( ICSBP/IRF -8 ) , is impaired in myeloid leukemias especially CML ( 27,46,47 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||25982..26051|149|These data suggest a distinct regulatory mechanism for these two IRFs .||||||||26055..26316|150|IRF-4 , similar to many other classical tumor suppressor genes p15INK4b , p16INK4a or p53 , may thus be a subject of alterations in the promoter methylation status leading to expression changes , which might contribute to the initiation and/or progression of cancer .|||||||||||||
Implicit|||||||||||Expansion|||||||||||26458..26522|152|For example , IRF-4 is primarily known for its oncogenic features .||||||||26524..26724|153|In multiple myeloma ( MM ) a translocation on chromosome 14q was reported to lead to a fusion gene of immunoglobulin heavy-chain ( IgH ) and IRF-4 resulting in a subsequent overexpression of IRF-4 ( 48,49 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||26726..26958|154|In addition , abundant IRF-4 expression was found to be a marker for various subsets of lymphomas , such as diffuse large B-cell lymphomas , primary effusion lymphoma , and marginal zone lymphoma , and adult T-cell leukemia ( 11,31,50 – 52 ) .||||||||26960..27014|155|This draws a more complex picture of the role of IRF-4 .|||||||||||||
EntRel||||||||||||||||||||||27477..27595|158|Figure and Table captions Figure 1 : Correlation of IRF-4 mRNA expression and nucleotide changes in the IRF-4 promoter .||||||||27597..27645|159|( A ) RT – PCR of different hematopoietic cell lines .|||||||||||||
EntRel||||||||||||||||||||||27597..27645|159|( A ) RT – PCR of different hematopoietic cell lines .||||||||27647..27813|160|( B ) nucleotide changes in the promoter of IRF-4-positive or - negative cells in comparison to the germline sequence at positions 98 , 111 and 1063 ( GenBank accession no .|||||||||||||
EntRel||||||||||||||||||||||27815..27918|161|U52683 ) , representing nucleotide − 1081 , − 1068 and − 116 ( 30 ) or − 1094 , − 1081 and − 129 ( 31 ) , respectively .||||||||27921..28000|162|Figure 2 : Expression of IRF-4 in hematopoietic cells after treatment with AzadC .|||||||||||||
EntRel||||||||||||||||||||||27921..28000|162|Figure 2 : Expression of IRF-4 in hematopoietic cells after treatment with AzadC .||||||||28002..28048|163|Representative cells and experiments are shown .|||||||||||||
EntRel||||||||||||||||||||||28050..28401|164|( A ) RT – PCR after incubation of CML-T1 and EM-2 with 0.5 , 1 and 3 µM AzadC for 72 h ; ( B ) RT – PCR after treatment of CML-T1 and EM-2 with 3 µM AzadC for 24 , 48 and 72 h ; ( C ) immunoblotting after treatment of CML-T1 and LAMA-84 with 1 and 3 µM AzadC for 72 h ; ( D ) RT – PCR after treatment of BV-173 for 24 , 48 and 72 h and RPMI-8226 for 72 h with 3 µM AzadC .||||||||28404..28480|165|Figure 3 : Restriction-PCR-assay of the IRF-4 promoter in hematopoietic cells .|||||||||||||
EntRel||||||||||||||||||||||28404..28480|165|Figure 3 : Restriction-PCR-assay of the IRF-4 promoter in hematopoietic cells .||||||||28482..28575|166|( A ) Simplified structure of the CpG sites in the human IRF-4 promoter region including exon 1 .|||||||||||||
EntRel||||||||||||||||||||||28482..28575|166|( A ) Simplified structure of the CpG sites in the human IRF-4 promoter region including exon 1 .||||||||28577..28683|167|Each CpG motif is shown as circle and numbered ( above , labeling beginning from the 3 ′ end moving upstream ) .|||||||||||||
EntRel||||||||||||||||||||||28577..28683|167|Each CpG motif is shown as circle and numbered ( above , labeling beginning from the 3 ′ end moving upstream ) .||||||||28685..28830|168|Restriction sites , fragments ( F1 , F2 ) of the restriction-PCR-assay and regions amplified after bisulfite treatment for sequencing are shown below .|||||||||||||
EntRel||||||||||||||||||||||28685..28830|168|Restriction sites , fragments ( F1 , F2 ) of the restriction-PCR-assay and regions amplified after bisulfite treatment for sequencing are shown below .||||||||28832..28905|169|The numbers in italics refer to the sequence data by Grossman et al. ( 30 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||28832..28905|169|The numbers in italics refer to the sequence data by Grossman et al. ( 30 ) .||||||||28907..28938|170|( B and C ) Restriction-PCR-assay .|||||||||||||
EntRel||||||||||||||||||||||28907..28938|170|( B and C ) Restriction-PCR-assay .||||||||28940..29126|171|Restriction of DNA with EcoRI ( E , no recognition site ) , HpaII ( H , sensitive ) , Bsp143II ( BII , sensitive ) , Bsh1236I ( BI , sensitive ) and MspI ( M , resistant ) and subsequent PCR amplification .|||||||||||||
Implicit|||||||||||Expansion|||||||||||28940..29126|171|Restriction of DNA with EcoRI ( E , no recognition site ) , HpaII ( H , sensitive ) , Bsp143II ( BII , sensitive ) , Bsh1236I ( BI , sensitive ) and MspI ( M , resistant ) and subsequent PCR amplification .||||||||29128..29244|172|Three representative IRF-4-negative ( K-562 , CML-T1 , EM-2 ) and two IRF-4-positive cell lines ( SD-1 , BV-173 ) are shown .|||||||||||||
EntRel||||||||||||||||||||||29128..29244|172|Three representative IRF-4-negative ( K-562 , CML-T1 , EM-2 ) and two IRF-4-positive cell lines ( SD-1 , BV-173 ) are shown .||||||||29246..29286|173|IRF-4 expression is denoted on the right .|||||||||||||
EntRel||||||||||||||||||||||29288..29336|174|( B ) PCR-fragment 1 ( F1 ) ; ( C ) PCR-fragment 2 ( F2 ) .||||||||29339..29410|175|Figure 4 : Methylation pattern of CpG sites in the IRF-4 promoter region .|||||||||||||
EntRel||||||||||||||||||||||29339..29410|175|Figure 4 : Methylation pattern of CpG sites in the IRF-4 promoter region .||||||||29412..29500|176|Methylation is detected via sequencing of bisulfite-treated DNA from hematopoietic cells .|||||||||||||
Implicit|||||||||||Expansion|||||||||||29412..29500|176|Methylation is detected via sequencing of bisulfite-treated DNA from hematopoietic cells .||||||||29502..29586|177|( A ) Schematic figure of the IRF-4 promoter region ( see Figure 3A ) for each cell line .|||||||||||||
Implicit|||||||||||Expansion|||||||||||29502..29586|177|( A ) Schematic figure of the IRF-4 promoter region ( see Figure 3A ) for each cell line .||||||||28577..28836|178|Each CpG motif is shown as circle and numbered ( above , labeling beginning from the 3 ′ end moving upstream ) , white circles mean no methylated clone ( from eight ) , gray circles mean one to four methylated clones and black circles mean five to eight methylated clones .|||||||||||||
EntRel||||||||||||||||||||||28577..28836|178|Each CpG motif is shown as circle and numbered ( above , labeling beginning from the 3 ′ end moving upstream ) , white circles mean no methylated clone ( from eight ) , gray circles mean one to four methylated clones and black circles mean five to eight methylated clones .||||||||29246..29286|179|IRF-4 expression is denoted on the right .|||||||||||||
EntRel||||||||||||||||||||||29246..29286|179|IRF-4 expression is denoted on the right .||||||||29895..30137|180|Below , CpG sites maybe responsible for methylation-dependent IRF-4 silencing ( arrows ) ; R1 , region with generally high methylation ; R2 , region with correlation between methylation and IRF-4 expression ; R3 , region with generally low methylation .|||||||||||||
Implicit|||||||||||Expansion|||||||||||29895..30137|180|Below , CpG sites maybe responsible for methylation-dependent IRF-4 silencing ( arrows ) ; R1 , region with generally high methylation ; R2 , region with correlation between methylation and IRF-4 expression ; R3 , region with generally low methylation .||||||||30139..30266|181|Putative binding sites for transcription factors are shown above ( 5 × AP1 , 3 × Sp1 , 2 × Ets-1 , 2 × κB , 1 × NF-3 , 1 × CD28RE , 1 × PU .1 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||30139..30266|181|Putative binding sites for transcription factors are shown above ( 5 × AP1 , 3 × Sp1 , 2 × Ets-1 , 2 × κB , 1 × NF-3 , 1 × CD28RE , 1 × PU .1 ) .||||||||30268..30357|182|( B ) Schematic figure of specific region 2 ( R2 ) : CpG sites from # 10 to # 22 are shown above .|||||||||||||
EntRel||||||||||||||||||||||30359..30427|183|Number of methylated clones ( from eight ) is shown for each cell line .||||||||30430..30499|184|Figure 5 : Investigation of putative mechanisms for IRF-4 deregulation .|||||||||||||
EntRel||||||||||||||||||||||30430..30499|184|Figure 5 : Investigation of putative mechanisms for IRF-4 deregulation .||||||||30501..30601|185|( A – C ) Influence of in vitro methylation on the activity of an IRF-4 promoter-reporter gene construct .|||||||||||||
Implicit|||||||||||Expansion|||||||||||30501..30601|185|( A – C ) Influence of in vitro methylation on the activity of an IRF-4 promoter-reporter gene construct .||||||||30603..30654|186|( A ) Control of complete methylation via restriction .|||||||||||||
Implicit|||||||||||Expansion|||||||||||30603..30654|186|( A ) Control of complete methylation via restriction .||||||||30656..30861|187|Digestion of the construct before ( lanes 2 , 4 and 6 ) and after methylation ( lanes 1 , 3 and 5 ) with respective methylation-sensitive ( HpaII , lanes 1 and 2 ) and - resistant endonucleases ( MspI , lanes 3 and 4 ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||30656..30861|187|Digestion of the construct before ( lanes 2 , 4 and 6 ) and after methylation ( lanes 1 , 3 and 5 ) with respective methylation-sensitive ( HpaII , lanes 1 and 2 ) and - resistant endonucleases ( MspI , lanes 3 and 4 ) .||||||||30863..31015|188|( B and C ) Reporter gene assays with non-methylated control ( co ) and in vitro methylated ( met ) IRF-4 promoter constructs and SD-1 ( B ) or Jurkat cells ( C ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||30863..31015|188|( B and C ) Reporter gene assays with non-methylated control ( co ) and in vitro methylated ( met ) IRF-4 promoter constructs and SD-1 ( B ) or Jurkat cells ( C ) .||||||||31017..31141|189|The promoter activity is displayed as fold increase to non-methylated construct ( via ratio of firefly to renilla luciferase ) .|||||||||||||
Implicit|||||||||||Expansion|||||||||||31017..31141|189|The promoter activity is displayed as fold increase to non-methylated construct ( via ratio of firefly to renilla luciferase ) .||||||||31143..31209|190|( D ) Expression of DNMT and MBP mRNA in various hematopoietic cells .|||||||||||||
Implicit|||||||||||Expansion|||||||||||31143..31209|190|( D ) Expression of DNMT and MBP mRNA in various hematopoietic cells .||||||||31211..31402|191|RT – PCR of various hematopoietic cells : SD-1 ( lane 1 ) , RPMI-8226 ( lane 2 ) , BV-173 ( lane 3 ) , U-937 ( lane 4 ) , CML-T1 ( lane 5 ) , LAMA-84 ( lane 6 ) , Jurkat ( lane 7 ) , EM-2 ( lane 8 ) and K-562 ( lane 9 ) .|||||||||||||
EntRel||||||||||||||||||||||31404..31432|192|β-Actin is used as reference .||||||||31435..31514|193|Figure 6 : Expression of ICSBP in hematopoietic cells after treatment with AzadC .|||||||||||||
EntRel||||||||||||||||||||||31435..31514|193|Figure 6 : Expression of ICSBP in hematopoietic cells after treatment with AzadC .||||||||31516..31552|194|Representative experiments are shown .|||||||||||||
